Literature DB >> 32591782

Pharmacokinetics of Cannabis Brownies: A Controlled Examination of Δ9-Tetrahydrocannabinol and Metabolites in Blood and Oral Fluid of Healthy Adult Males and Females.

Tory R Spindle1, Edward J Cone1, Evan S Herrmann1, John M Mitchell2, Ronald Flegel3, Charles LoDico3, George E Bigelow1, Ryan Vandrey1.   

Abstract

Oral cannabis products (a.k.a. "edibles") have increased in popularity in recent years. Most prior controlled pharmacokinetic evaluations of cannabis have focused on smoked cannabis and included males who were frequent cannabis users. In this study, 17 healthy adults (8 females), with no cannabis use in at least the past 2 months, completed 4 double-blind outpatient sessions where they consumed cannabis brownies containing Δ9-tetrahydrocannabinol (THC) doses of 0, 10, 25 or 50 mg. Whole blood and oral fluid specimens were collected at baseline and for 8 h post-brownie ingestion. Enzyme-linked immunosorbent assay (ELISA) and liquid chromatography-tandem mass spectrometry (LC-MS-MS) were used to measure THC and relevant metabolites. In whole blood, concentrations of THC and 11-hydroxy-THC (11-OH-THC) peaked 1.5-2 h after brownie consumption, decreased steadily thereafter, and typically returned to baseline within 8 h. Blood concentrations for 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THCCOOH) and THCCOOH-glucuronide were higher than THC and 11-OH-THC and these metabolites were often still detected 8 h post-brownie consumption. Women displayed higher peak concentrations for THC and all metabolites in whole blood compared to men, at least partially owing to their lower body weight/body mass index. Detection of THC in oral fluid was immediate and appeared to reflect the degree of cannabis deposition in the oral cavity, not levels of THC circulating in the blood. THC concentrations were substantially higher in oral fluid than in blood; the opposite trend was observed for THCCOOH. Agreement between ELISA and LC-MS-MS results was high (i.e., over 90%) for blood THCCOOH and oral fluid THC but comparatively low for oral fluid THCCOOH (i.e., 67%). Following oral consumption of cannabis, THC was detected in blood much later, and at far lower peak concentrations, compared to what has been observed with inhaled cannabis. These results are important given the widespread use of toxicological testing to detect recent use of cannabis and/or to identify cannabis intoxication.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32591782      PMCID: PMC7549129          DOI: 10.1093/jat/bkaa067

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  20 in total

1.  Toking, Vaping, and Eating for Health or Fun: Marijuana Use Patterns in Adults, U.S., 2014.

Authors:  Gillian L Schauer; Brian A King; Rebecca E Bunnell; Gabbi Promoff; Timothy A McAfee
Journal:  Am J Prev Med       Date:  2015-08-12       Impact factor: 5.043

Review 2.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

3.  Comparison of cannabinoid concentrations in oral fluid and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint.

Authors:  Marie Fabritius; Haithem Chtioui; Giovanni Battistella; Jean-Marie Annoni; Kim Dao; Bernard Favrat; Eleonora Fornari; Estelle Lauer; Philippe Maeder; Christian Giroud
Journal:  Anal Bioanal Chem       Date:  2013-11-08       Impact factor: 4.142

4.  Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.

Authors:  Ryan Vandrey; Evan S Herrmann; John M Mitchell; George E Bigelow; Ronald Flegel; Charles LoDico; Edward J Cone
Journal:  J Anal Toxicol       Date:  2017-03-01       Impact factor: 3.367

5.  Bongs and baby boomers: Trends in cannabis use among older Australians.

Authors:  Victoria Kostadinov; Ann Roche
Journal:  Australas J Ageing       Date:  2016-10-12       Impact factor: 2.111

6.  Validation of an enzyme immunoassay for detection and semiquantification of cannabinoids in oral fluid.

Authors:  David M Schwope; Garry Milman; Marilyn A Huestis
Journal:  Clin Chem       Date:  2010-04-01       Impact factor: 8.327

7.  Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.

Authors:  Tory R Spindle; Edward J Cone; Nicolas J Schlienz; John M Mitchell; George E Bigelow; Ronald Flegel; Eugene Hayes; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2019-05-01       Impact factor: 3.367

8.  Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans.

Authors:  S R Wachtel; M A ElSohly; S A Ross; J Ambre; H de Wit
Journal:  Psychopharmacology (Berl)       Date:  2002-04-19       Impact factor: 4.530

9.  Smoking, Vaping, and Use of Edibles and Other Forms of Marijuana Among U.S. Adults.

Authors:  Stacey Steigerwald; Peggy O Wong; Beth E Cohen; Julie H Ishida; Marzieh Vali; Erin Madden; Salomeh Keyhani
Journal:  Ann Intern Med       Date:  2018-08-28       Impact factor: 25.391

10.  Tetrahydrocannabinol and two of its metabolites in whole blood using liquid chromatography-tandem mass spectrometry.

Authors:  Cynthia Coulter; Elizabeth Miller; Katherine Crompton; Christine Moore
Journal:  J Anal Toxicol       Date:  2008-10       Impact factor: 3.367

View more
  7 in total

1.  Preliminary Eye-Tracking Data as a Nonintrusive Marker for Blood Δ-9-Tetrahydrocannabinol Concentration and Drugged Driving.

Authors:  Ali Shahidi Zandi; Felix J E Comeau; Robert E Mann; Patricia Di Ciano; Eliyas P Arslan; Thomas Murphy; Bernard Le Foll; Christine M Wickens
Journal:  Cannabis Cannabinoid Res       Date:  2021-08-24

2.  Cannabis Use Disorder: A Behavioral Economic Perspective.

Authors:  Elizabeth R Aston; Benjamin L Berey
Journal:  Curr Addict Rep       Date:  2022-01-07

3.  Orally administered cannabidiol does not produce false-positive tests for Δ9 -tetrahydrocannabinol on the Securetec DrugWipe® 5S or Dräger DrugTest® 5000.

Authors:  Danielle McCartney; Richard C Kevin; Anastasia S Suraev; Christopher Irwin; Ronald R Grunstein; Camilla M Hoyos; Iain S McGregor
Journal:  Drug Test Anal       Date:  2021-08-30       Impact factor: 3.234

4.  Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products.

Authors:  Cecilia L Bergeria; Tory R Spindle; Edward J Cone; Dennis Sholler; Elia Goffi; John M Mitchell; Ruth E Winecker; George E Bigelow; Ronald Flegel; Ryan Vandrey
Journal:  J Anal Toxicol       Date:  2022-07-14       Impact factor: 3.220

5.  Sensitivity, Specificity and Accuracy of a Novel EEG-Based Objective Test, the Cognalyzer®, in Detecting Cannabis Psychoactive Effects.

Authors:  Alison C McDonald; Israel Gasperin Haaz; Weikai Qi; David C Crowley; Najla Guthrie; Malkanthi Evans; Dan Bosnyak
Journal:  Adv Ther       Date:  2021-04-07       Impact factor: 3.845

Review 6.  Pharmacokinetics of Cannabis and Its Derivatives in Animals and Humans During Pregnancy and Breastfeeding.

Authors:  Anaëlle Monfort; Ema Ferreira; Grégoire Leclair; Gregory Anton Lodygensky
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988

7.  Δ9-Tetrahydrocannabinol discrimination: Effects of route of administration in rats.

Authors:  Jenny L Wiley; Shanequa I Taylor; Julie A Marusich
Journal:  Drug Alcohol Depend       Date:  2021-06-23       Impact factor: 4.852

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.